Trump plans groundbreaking decree: Proices in the USA!

Trump plans groundbreaking decree: Proices in the USA!

USA - US President Donald Trump has recently announced a significant announcement that could affect health policy and international relationship with Syria. During a conversation with Turkish President Recep Tayyip Erdogan, Trump said that he was testing the lifting of sanctions against Syria in order to enable the country to start again. This consideration is part of a larger plan that also deals with the exorbitant prices for prescription drugs in the United States.

Trump announced that he signed a decree that is described as one of the "most consequent" in the history of the United States. With this step, he plans to reduce prices for prescription drugs by 30 to 80 percent. The President criticized the high pharmaceutical prices in international comparison and promised American citizens justice. There is currently no central state price regulation in the United States, which leads to the considerable costs. Trump speaks that American patients co -finance the so -called "socialist health systems" in other countries, while pharmaceutical companies have a strong discount on their products in order to gain access to foreign markets.

Price regulation measures and their effects

Trump's announced measures relate to the principle of the "Most Favored Nation", which is intended to ensure that the United States does not pay more for medication than the country with the lowest price. The U.S. Ministry of Health is commissioned to conduct new price negotiations and to proceed against pricing policy in other countries perceived as unfair. Specific goals for price reductions should be determined within 30 days.

A study by the advisory company Simon-Kucher already analyzes the far-reaching effects on the global pharmaceutical industry and in particular on German companies. Trump warns that a decline in sales in the USA could increase pressure on pharmaceutical companies to increase its prices in other countries. Experts fear that the industry will come under pressure to delay market entries in Germany or Europe in order to avoid low price references. In addition, the introduction of tariffs to pharmaceuticals from the EU could endanger the industry and its research.

The announcement already put pressure on the pharmaceutical industry, and it is feared that high tariffs on medication could complicate the trade relationships between the USA and Europe. While Trump praised the customs talks with China as a "complete restart", it remains to be seen what economic consequences his measures will have on international drug prices.

In conclusion, it should be mentioned that criticism of Trump's scope for action becomes loud in the political landscape. Ex-US President Joe Biden sharply condemned Trump's dealings with Russia in an interview. At the same time, the US Federal Reserve leaves the key interest rate at a high level, despite the continuing demands of Trump after a reduction.